Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

by · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
  • Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
  • Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
  • Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
  • Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
  • Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
  • Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
  • Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
  • Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
  • Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Abbott Laboratories Stock Down 0.9%

ABT traded down $1.18 during trading on Thursday, hitting $123.82. 3,232,089 shares of the company’s stock were exchanged, compared to its average volume of 5,591,480. Abbott Laboratories has a fifty-two week low of $111.02 and a fifty-two week high of $141.23. The stock has a market cap of $215.30 billion, a P/E ratio of 15.51, a PEG ratio of 2.06 and a beta of 0.72. The business’s 50 day moving average is $126.12 and its two-hundred day moving average is $129.14. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same period in the previous year, the firm posted $1.21 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds have recently made changes to their positions in the stock. IMG Wealth Management Inc. lifted its position in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter valued at about $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories in the third quarter worth about $31,000. Anfield Capital Management LLC lifted its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $32,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ABT shares. Evercore ISI raised their target price on Abbott Laboratories from $142.00 to $144.00 and gave the company an “outperform” rating in a report on Monday, January 5th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. Jefferies Financial Group boosted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Finally, Barclays raised their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $147.68.

Get Our Latest Stock Analysis on Abbott Laboratories

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

See Also